

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Er Sheng Gong¹

¹ Gannan Medical University

Potential competing interests: No potential competing interests to declare.

Based on the literature search, no studies have reported on utilizing isobutylphenol to target the Nrf2 pathway for the mitigation of Alzheimer's disease, suggesting the novelty of this research approach. This study illustrated that Isoeugenol activated Nrf2 and displayed anti-oxidant and anti-inflammatory effects and reduced the levels of A β peptides in in vitro and in vivo models of AD. In addition, Isoeugenol improved the memory deficits observed in APP/PS1 mice, indicating its potential to ameliorate AD hallmarks. The data presented in this research is thorough and the logic is sound, warranting its publication in this journal. However, several issues should be addressed.

ABSTRACT

The abstract and conclusion should emphasize the presentation of research findings, rather than extensive discussions on the background. Ideally, the word count for the abstract should be around 300 words.

INTRODUCTION

"For more than a decade that AD....". It seems that conjunction use may be incorrect here.

"When occurring after 65 years-old....". The word "years-old" doesn't seem to fit this context. Consider replacing it with a different one.

"AD is classified as sporadic or late-onset AD (LOAD),". It appears that you have an unnecessary comma in a compound predicate. Consider removing it.

Please review the entire document for any grammatical errors and make necessary corrections.

REFERENCE

Ensure uniformity in the capitalization of titles in the references.